Johnson & Johnson bate as expectativas de ganhos do quarto trimestre, projeta forte crescimento para 2025-2030. Johnson & Johnson beats Q4 earnings expectations, projects strong growth for 2025-2030.

A J&J superou as expectativas de Wall Street para seus ganhos no quarto trimestre, com vendas de 5,3% a US$ 22,52 bilhões. Johnson & Johnson (J&J) exceeded Wall Street expectations for its fourth-quarter earnings, with sales up 5.3% to $22.52 billion. As vendas de medicamentos contra o câncer, particularmente Darzalex, aumentaram 19%, contribuindo significativamente para o crescimento. Cancer drug sales, particularly Darzalex, surged 19%, contributing significantly to the growth. A J&J projeta vendas de 2025 entre US$ 90,9 bilhões e US$ 91,7 bilhões e prevê uma taxa de crescimento anual composta de 5% a 7% para 2025-2030, excluindo os impactos cambiais. J&J projects 2025 sales between $90.9 billion and $91.7 billion and forecasts a 5%-7% compound annual growth rate for 2025-2030, excluding currency impacts.